{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:59:10Z","timestamp":1790035150922,"version":"4.0.1"},"reference-count":129,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Nucleophosmin (NPM1) gene mutations rarely occur in non-acute myeloid neoplasms (MNs) with &lt;20% blasts. Among nearly 10,000 patients investigated so far, molecular analyses documented NPM1 mutations in around 2% of myelodysplastic syndrome (MDS) cases, mainly belonging to MDS with excess of blasts, and 3% of myelodysplastic\/myeloproliferative neoplasm (MDS\/MPN) cases, prevalently classified as chronic myelomonocytic leukemia. These uncommon malignancies are associated with an aggressive clinical course, relatively rapid progression to overt acute myeloid leukemia (AML) and poor survival outcomes, raising controversies on their classification as distinct clinico-pathologic entities. Furthermore, fit patients with NPM1-mutated MNs with &lt;20% blasts could benefit most from upfront intensive chemotherapy for AML rather than from moderate intensity MDS-directed therapies, although no firm conclusion can currently be drawn on best therapeutic approaches, due to the limited available data, obtained from small and mainly retrospective series. Caution is also suggested in definitely diagnosing NPM1-mutated MNs with blast count &lt;20%, since NPM1-mutated AML cases frequently present dysplastic features and multilineage bone marrow cells showing abnormal cytoplasmic NPM1 protein delocalization by immunohistochemical staining, therefore belonging to NPM1-mutated clone regardless of blast morphology. Further prospective studies are warranted to definitely assess whether NPM1 mutations may become sufficient to diagnose AML, irrespective of blast percentage.<\/jats:p>","DOI":"10.3390\/ijms21238975","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T09:04:15Z","timestamp":1606381455000},"page":"8975","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["NPM1-Mutated Myeloid Neoplasms with &lt;20% Blasts: A Really Distinct Clinico-Pathologic Entity?"],"prefix":"10.3390","volume":"21","author":[{"given":"Fabio","family":"Forghieri","sequence":"first","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5122-5574","authenticated-orcid":false,"given":"Vincenzo","family":"Nasillo","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambra","family":"Paolini","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bettelli","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Pioli","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Giusti","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gilioli","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5436-7794","authenticated-orcid":false,"given":"Corrado","family":"Colasante","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Acquaviva","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Policlinico, 41124 Modena, Italy"},{"name":"Department of Clinical and Experimental Medicine, University of Sassari, 07100 Sassari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Riva","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Unit\u00e0 Sanitaria Locale, 41126 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8936-1114","authenticated-orcid":false,"given":"Patrizia","family":"Barozzi","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3518-2006","authenticated-orcid":false,"given":"Rossana","family":"Maffei","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Potenza","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6431-6878","authenticated-orcid":false,"given":"Roberto","family":"Marasca","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Fozza","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Sassari, 07100 Sassari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0981-2542","authenticated-orcid":false,"given":"Enrico","family":"Tagliafico","sequence":"additional","affiliation":[{"name":"Center for Genome Research, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Trenti","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Unit\u00e0 Sanitaria Locale, 41126 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Comoli","sequence":"additional","affiliation":[{"name":"Pediatric Hematology\/Oncology Unit and Cell Factory, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Longo","sequence":"additional","affiliation":[{"name":"Division of Oncologic Medicine, Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Luppi","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrc1885","article-title":"Nucleophosmin and cancer","volume":"6","author":"Grisendi","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2006-07-012252","article-title":"Acute myeloid leukemia carrying cytoplasmic\/mutated nucleophosmin (NPMc + AML): Biologic and clinical features","volume":"109","author":"Falini","year":"2007","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/leu.2009.124","article-title":"Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: Molecular basis and clinical implications","volume":"23","author":"Falini","year":"2009","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2010-08-299990","article-title":"Acute myeloid leukemia with mutated nucleophosmin (NPM1): Is it a distinct entity?","volume":"117","author":"Falini","year":"2011","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.2019004226","article-title":"NPM1-mutated acute myeloid leukemia: From bench to bedside","volume":"136","author":"Falini","year":"2020","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41586-020-2256-2","article-title":"Composition-dependent thermodynamics of intracellular phase separation","volume":"581","author":"Riback","year":"2020","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41467-018-03255-3","article-title":"Self-interaction of NPM1 modulates multiple mechanisms of liquid-liquid phase separation","volume":"9","author":"Mitrea","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/s41588-019-0502-z","article-title":"Germline NPM1 mutations lead to altered rRNA 2\u2032-Omethylation and cause dyskeratosis congenita","volume":"51","author":"Nachmani","year":"2019","journal-title":"Nat. Genet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","article-title":"Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance","volume":"127","author":"Grimwade","year":"2016","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/leu.2017.30","article-title":"Biological and clinical consequences of NPM1 mutations in AML","volume":"31","author":"Heath","year":"2017","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood.2019001240","article-title":"Molecular roulette: Nucleophosmin mutations in AML are orchestrated through N-nucleotide addition by TdT","volume":"134","author":"Borrow","year":"2019","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood-2006-03-007013","article-title":"Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia","volume":"108","author":"Falini","year":"2006","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1172\/JCI97117","article-title":"Leukemogenic nucleophosmin mutation disrupts the transcription factor hub regulating granulo-monocytic fates","volume":"128","author":"Gu","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","article-title":"Mutant NPM1 maintains the leukemic state through HOX expression","volume":"34","author":"Brunetti","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccell.2018.08.013","article-title":"Location, location, location: Mutant NPM1c cytoplasmic localization is required to maintain stem cell genes in AML","volume":"34","author":"Uckelmann","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/bloodadvances.2018023432","article-title":"NPM1 mutated AML can relapse with wild-type NPM1: Persistent clonal hematopoiesis can drive relapse","volume":"2","author":"Meggendorfer","year":"2018","journal-title":"Blood Adv."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Forghieri, F., Comoli, P., Marasca, R., Potenza, L., and Luppi, M. (2018). Minimal\/Measurable Residual Disease monitoring in NPM1-mutated acute myeloid leukemia: A clinical viewpoint and perspectives. Int. J. Mol. Sci, 19.","DOI":"10.3390\/ijms19113492"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2009-01-197871","article-title":"AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features","volume":"114","author":"Haferlach","year":"2009","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1182\/blood-2009-07-230995","article-title":"The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplication","volume":"114","author":"Micol","year":"2009","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1200\/JCO.19.00416","article-title":"Chromosomal abnormalities and prognosis in NPM1-mutated acute myeloid leukemia: A pooled analysis of individual patient data from nine international cohorts","volume":"37","author":"Angenendt","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1182\/blood-2005-05-2164","article-title":"Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations","volume":"106","author":"Schlenk","year":"2005","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","article-title":"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia","volume":"111","author":"Gale","year":"2008","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2012-06-431122","article-title":"Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: Relevance to postremission therapy","volume":"121","author":"Pratcorona","year":"2013","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","article-title":"Differential impact of allelic ratio and insertion site in FLT3-ITD positive AML with respect to allogeneic transplantation","volume":"124","author":"Schlenk","year":"2014","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood-2014-02-554667","article-title":"Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia","volume":"124","author":"Linch","year":"2014","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1182\/blood-2017-09-807438","article-title":"The impact of age, NPM1(mut), and FLT3(ITD) allelic ratio in patients with acute myeloid leukemia","volume":"131","author":"Straube","year":"2018","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/bloodadvances.2018020305","article-title":"Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia","volume":"2","author":"Sakaguchi","year":"2018","journal-title":"Blood Adv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/cncr.31885","article-title":"Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes","volume":"125","author":"Boddu","year":"2019","journal-title":"Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood.2019002697","article-title":"Impact of NPM1\/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia","volume":"135","author":"Thiede","year":"2020","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Eisfeld, A.K., Kohlschmidt, J., Mims, A., Nicolet, D., Walker, C.J., Blachly, J.S., Carroll, A.J., Papaioannou, D., Kolitz, J.E., and Powell, B.E. (2020). Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years. Leukemia.","DOI":"10.1038\/s41375-020-0872-3"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: A consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3324\/haematol.2009.017822","article-title":"Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: Flexibility may help","volume":"95","author":"Falini","year":"2010","journal-title":"Haematologica"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/leu.2010.124","article-title":"Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML","volume":"24","author":"Dicker","year":"2010","journal-title":"Leukemia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/leu.2010.299","article-title":"Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms","volume":"25","author":"Schnittger","year":"2011","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1182\/blood.V124.21.700.700","article-title":"In AML secondary to MDS NPM1 mutations are late events, less frequent, and associated with a different pattern of molecular mutations than in de novo AML","volume":"124","author":"Schnittger","year":"2014","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/modpathol.2012.218","article-title":"Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia","volume":"26","author":"Courville","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Fernandez-Mercado, M., Yip, B.H., Pellagatti, A., Davies, C., Larrayoz, M.J., Kondo, T., P\u00e9rez, C., Killick, S., McDonald, E.J., and Odero, M.D. (2012). Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0042334"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"ref_43","first-page":"456","article-title":"Genetic alteration patterns and clinical outcomes of elderly and secondary acute myeloid leukemia","volume":"35","author":"Wang","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/10428194.2020.1719089","article-title":"Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes","volume":"61","author":"Badar","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2141.2006.06081.x","article-title":"C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders","volume":"133","author":"Caudill","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_46","first-page":"1147","article-title":"Mutations and promoter methylation status of NPM1 in myeloproliferative disorders","volume":"91","author":"Oki","year":"2006","journal-title":"Haematologica"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.leukres.2006.03.013","article-title":"NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype","volume":"31","author":"Zhang","year":"2007","journal-title":"Leuk. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1080\/10428190701615900","article-title":"Lack of nucleophosmin mutation in patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities","volume":"48","author":"Shiseki","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1080\/10428190802541815","article-title":"Abnormal cytoplasmic dyslocation and\/or reduction of nucleophosmin protein level rarely occurs in myelodysplastic syndromes","volume":"49","author":"Ishikawa","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/leu.2008.17","article-title":"NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features","volume":"22","author":"Andersen","year":"2008","journal-title":"Leukemia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1002\/cncr.24501","article-title":"The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes","volume":"115","author":"Bacher","year":"2009","journal-title":"Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/j.leukres.2009.05.015","article-title":"Detection of FLT3\/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia","volume":"33","author":"Chen","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.3324\/haematol.2010.021808","article-title":"Transcription factor mutations in myelodysplastic\/myeloproliferative neoplasms","volume":"95","author":"Ernst","year":"2010","journal-title":"Haematologica"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Rocquain, J., Carbuccia, N., Trouplin, V., Raynaud, S., Murati, A., Nezri, M., Tadrist, Z., Olschwang, S., Vey, N., and Birnbaum, D. (2010). Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-401"},{"key":"ref_55","first-page":"809","article-title":"Study of NPM1 gene mutations in patients with primary myelodysplastic syndromes","volume":"31","author":"Li","year":"2010","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3324\/haematol.2010.025494","article-title":"IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis","volume":"95","author":"Thol","year":"2010","journal-title":"Haematologica"},{"key":"ref_57","first-page":"671","article-title":"Investigation of FLT3-ITD and NPM1 mutations in patients with myelodysplastic syndrome and mixed myeloid diseases","volume":"56","author":"Gritsaev","year":"2010","journal-title":"Vopr. Onkol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08381.x","article-title":"ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia","volume":"151","author":"Trouplin","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effects of point mutations in myelodyplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.3324\/haematol.2011.043687","article-title":"Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells","volume":"96","author":"Bacher","year":"2011","journal-title":"Haematologica"},{"key":"ref_61","first-page":"793","article-title":"Screening of hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes","volume":"66","author":"Traina","year":"2011","journal-title":"Clinics"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1309\/AJCPEI9XU8PYBCIO","article-title":"FLT3 and NPM1 mutations in myelodysplastic syndromes. Frequency and potential value for predicting progression to acute myeloid leukemia","volume":"135","author":"Bains","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/leu.2013.58","article-title":"Clonal diversity of recurrently mutated genes in myelodysplastic syndromes","volume":"27","author":"Walter","year":"2013","journal-title":"Leukemia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"8589","DOI":"10.1073\/pnas.1407688111","article-title":"Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers","volume":"111","author":"Xu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.3109\/10428194.2015.1026900","article-title":"NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic\/myeloproliferative neoplasms","volume":"56","author":"Forghieri","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1182\/blood-2015-08-663237","article-title":"Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression","volume":"126","author":"Cargo","year":"2015","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/ejh.12549","article-title":"Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation","volume":"96","author":"Peng","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"30084","DOI":"10.18632\/oncotarget.8310","article-title":"Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms","volume":"7","author":"Bartels","year":"2016","journal-title":"Oncotarget"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/ajcp\/aqw016","article-title":"Targeted Next-Generation Sequencing in myelodysplastic syndrome and chronic myelomonocytic leukemia aids diagnosis in challenging cases and identifies frequent spliceosome mutations in transformed acute myeloid leukemia","volume":"145","author":"Reinig","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng.3742","article-title":"Dynamics of clonal evolution in myelodysplastic syndromes","volume":"49","author":"Makishima","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e614","DOI":"10.1002\/ajh.24861","article-title":"Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance","volume":"92","author":"Vallapureddy","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"82475","DOI":"10.18632\/oncotarget.19628","article-title":"Implications of mutational spectrum in myelodysplastic syndromes based on targeted next-generation sequencing","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/ajh.25267","article-title":"Mutations and karyotype predict treatment response in myelodysplastic syndromes","volume":"93","author":"Idossa","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/s41409-019-0444-1","article-title":"Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes","volume":"54","author":"Hamilton","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/bloodadvances.2018026989","article-title":"NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy","volume":"3","author":"Sasaki","year":"2019","journal-title":"Blood Adv."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"106190","DOI":"10.1016\/j.leukres.2019.106190","article-title":"Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia","volume":"84","author":"Hwang","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/ajh.25592","article-title":"The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia","volume":"94","author":"Zheng","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_82","unstructured":"Vantyghem, S., Peterlin, P., Th\u00e9pot, S., M\u00e9nard, A., Dubruille, V., Debord, C., Guillaume, T., Garnier, A., Le Bourgeois, A., and Wuilleme, S. (2020). Diagnosis and prognosis are comforted by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study. Haematologica."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/16078454.2020.1765561","article-title":"Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation","volume":"25","author":"Wang","year":"2020","journal-title":"Hematology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40164-019-0158-5","article-title":"Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia","volume":"9","author":"Yu","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/bjh.16628","article-title":"NPM1 mutation with DNMT3A wild type defines a subgroup of MDS with particularly favorable outcomes after decitabine therapy","volume":"198","author":"Wu","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Yun, S., Geyer, S.M., Komrokji, R.S., Al Ali, N.H., Song, J., Hussaini, M., Sweet, K.L., Lancet, J.E., List, A.F., and Padron, E. (2020). Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). Leukemia.","DOI":"10.1038\/s41375-020-0997-4"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/bloodadvances.2019000090","article-title":"Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms","volume":"3","author":"Patel","year":"2019","journal-title":"Blood Adv."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11899-020-00592-3","article-title":"NPM1 biology in myeloid neoplasia","volume":"15","author":"Patel","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"60","DOI":"10.6004\/jnccn.2017.0007","article-title":"Myelodysplastic Syndromes. NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Greenberg","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1097\/HS9.0000000000000150","article-title":"Diagnosis and treatment of chronic myelomonocytic leukemia in adults: Recommendations from the European Hematology Association and the European LeukemiaNet","volume":"2","author":"Itzykson","year":"2018","journal-title":"HemaSphere"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood.2019004229","article-title":"Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms","volume":"136","author":"Palomo","year":"2020","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2016.71.0806","article-title":"Clinical implications of genetic mutations in myelodysplastic syndrome","volume":"35","author":"Kennedy","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3324\/haematol.2020.248955","article-title":"Myelodysplastic syndromes: Moving towards personalized management","volume":"105","author":"Tobiasson","year":"2020","journal-title":"Haematologica"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Caponetti, G.C., and Bagg, A. (2020). Mutations in myelodysplastic syndromes: Core abnormalities and CHIPing away at the edges. Int. J. Lab. Hematol.","DOI":"10.1111\/ijlh.13284"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","article-title":"Diagnosis and treatment of primary myelodysplastic syndromes in adults: Recommendations from European LeukemiaNet","volume":"122","author":"Malcovati","year":"2013","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjh.16175","article-title":"Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia","volume":"188","author":"Palomo","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11912-020-0869-0","article-title":"Myelodysplastic syndromes: How to recognize risk and avoid acute myeloid leukemia transformation","volume":"22","author":"Hospital","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood.2019000942","article-title":"Genetics of progression from MDS to secondary leukemia","volume":"136","author":"Menssen","year":"2020","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.beha.2018.10.002","article-title":"What biologic factors predict for transformation to AML?","volume":"31","author":"Bejar","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/bjh.16206","article-title":"How to manage adults with myelodysplastic syndrome","volume":"189","author":"Fenaux","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.25104","article-title":"Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management","volume":"93","author":"Patnaik","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1182\/blood-2006-06-026716","article-title":"Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification","volume":"108","author":"Pasqualucci","year":"2006","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/blood-2009-08-240457","article-title":"Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1)","volume":"115","author":"Falini","year":"2010","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1182\/blood-2010-09-307314","article-title":"The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status","volume":"116","author":"Rozman","year":"2010","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1182\/blood-2009-03-208587","article-title":"The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model","volume":"115","author":"Cheng","year":"2010","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2014.257","article-title":"Mouse models of NPM1-mutated acute myeloid leukemia: Biological and clinical implications","volume":"29","author":"Sportoletti","year":"2015","journal-title":"Leukemia"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/nm.4210","article-title":"DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling","volume":"22","author":"Guryanova","year":"2016","journal-title":"Nat. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/leu.2013.77","article-title":"A powerful molecular synergy between mutant nucleophosmin anf Flt3-ITD drives acute myeloid leukemia in mice","volume":"27","author":"Mupo","year":"2013","journal-title":"Leukemia"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/leu.2013.114","article-title":"NPMc+ and FLT3-ITD mutations cooperate in inducing acute leukaemia in a novel mouse model","volume":"27","author":"Mallardo","year":"2013","journal-title":"Leukemia"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1182\/blood-2017-01-760595","article-title":"Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia","volume":"130","author":"Dovey","year":"2017","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1182\/blood-2017-09-804062","article-title":"A scale of \u201cbad\u201d co-mutations in NPM1-driven AML","volume":"130","author":"Falini","year":"2017","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/s41375-018-0368-6","article-title":"Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis","volume":"33","author":"Loberg","year":"2019","journal-title":"Leukemia"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1126\/science.aax5863","article-title":"Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia","volume":"367","author":"Uckelmann","year":"2020","journal-title":"Science"},{"key":"ref_114","unstructured":"Forghieri, F., Nasillo, V., Colasante, P., Potenza, L., and Luppi, M. (2020, February 27). Are We Ready to Fight Against NPM1-Mutated Preleukemic Clones in Humans?. Available online: https:\/\/science.sciencemag.org\/content\/367\/6477\/586\/tab-e-letters."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.leukres.2017.01.027","article-title":"Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia","volume":"56","author":"Patel","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41375-018-0319-2","article-title":"Single cell analysis of clonal architecture in acute myeloid leukaemia","volume":"33","author":"Potter","year":"2019","journal-title":"Leukemia"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Herudkova, Z., Culen, M., Folta, A., Jeziskova, I., Cerna, J., Loja, T., Tom, N., Smejkal, J., Semerad, L., and Dvorakova, D. (2019). Clonal hierarchy of main molecular lesions in acute myeloid leukaemia. Br. J. Haematol.","DOI":"10.1111\/bjh.16341"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"Hovestadt","year":"2019","journal-title":"Cell"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2013-01-479188","article-title":"Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia","volume":"122","author":"Bullinger","year":"2013","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/leu.2017.217","article-title":"Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML","volume":"31","author":"Herold","year":"2017","journal-title":"Leukemia"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/s41467-019-09745-2","article-title":"Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation","volume":"10","author":"Cocciardi","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1172\/JCI129126","article-title":"Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia","volume":"130","author":"Klossowski","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1056\/NEJMc1509584","article-title":"Dactinomycin in NPM1-mutated acute myeloid leukemia","volume":"373","author":"Falini","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/ejh.13438","article-title":"Dactinomycin in acute myeloid leukemia with NPM1 mutations","volume":"105","author":"Beziat","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of older patients with NPM1-mutated AML: Current treatments and the promise of venetoclax-based regimens","volume":"4","author":"Lachowiez","year":"2020","journal-title":"Blood Adv."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/leu.2017.17","article-title":"The clonal origins of leukemic progression of myelodysplasia","volume":"31","author":"Kim","year":"2017","journal-title":"Leukemia"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Falini, B., Brunetti, L., and Martelli, M.P. (2020). How I diagnose and treat NPM1-mutated AML. Blood.","DOI":"10.1182\/blood.2020008211"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/23\/8975\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:37:39Z","timestamp":1760179059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/23\/8975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,26]]},"references-count":129,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["ijms21238975"],"URL":"https:\/\/doi.org\/10.3390\/ijms21238975","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,26]]}}}